Industry News — Clinical Updates

European Commission Approves Eylea for Treatment of DME

The European Commission has approved Eylea (aflibercept; Regeneron Pharmaceuticals, Inc., Tarrytown, New York) for the treatment of visual impairment due to diabetic macular edema (DME). Bayer Healthcare (Leverkusen, Germany) plans to launch aflibercept for DME in the European Union (EU) this quarter.

Regulatory submissions for aflibercept for DME have also been made in Japan, Asia Pacific, and Latin America. In Japan, aflibercept has also been submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia. A regulatory submission has also been made in the US and the EU for aflibercept for the treatment of macular edema following branch retinal vein occlusion.

Updated August 11, 2014